Lumira Capital primarily invests in later stage biopharmaceutical companies typically having at least preliminary clinical proof of concept data and will also consider later stage medical device companies. The firm's history goes back to 1989 when the company was established as MDS Capital Corp. The company changed its name to Lumira Capital in September 2007 as part of a corporate repositioning to build on its strength in the North American health and life science sector. Typically, Lumira's initial investment size is $5 to 10 million, and the firm concentrates its investments in the U.S. and Canada.

Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.